Newer immunomodulators in rheumatoid arthritis: A cautionary tale for cardiologists

Authors

  • Surendhar.G Associate Consultant, Cardiology, Kauvery Hospital, Vadapalani, Chennai
  • Manokar Panchanatham Senior Interventional, Cardiology Kauvery Hospital, Vadapalani, Chennai
  • Sundar C Senior Consultant, Cardiology, Kauvery Hospital, Vadapalani, Chennai
  • Nithesh Kumar Associate Consultant - Interventional Cardiology, Kauvery Hospital, Vadapalani, Chennai
  • Selvaprakash E Consultant, Department of cardiology Kauvery Hospital, Vadapalani, Chennai

Keywords:

Ankylosing spondylosis, Tofacitinib, Rheumatoid arthritis, Immunosuppressive medications

Abstract

Cardiotoxicity can result in serious complications, including heart failure, cardiomyopathy, arrhythmias, myocardial infarction (heart attack), myocarditis (inflammation of the heart muscle), and sudden death Two cases of suspected drug-induced cardiac events are presented, highlighting the possible real-world implications of these risks.

Downloads

Published

2025-08-11

How to Cite

Surendhar.G, Manokar Panchanatham, Sundar C, Nithesh Kumar, & Selvaprakash E. (2025). Newer immunomodulators in rheumatoid arthritis: A cautionary tale for cardiologists. Kauverian Medical Journal, 2(10), 23–27. Retrieved from http://kauverianjournal.com/index.php/research/article/view/184

Issue

Vol. 2 No. 10 (2025): August

Section

Articles